BORTEZOMIB [VELCADE] - VELCADE 3.5MG | MILLIONHEALTHPHARMA

BORTEZOMIB 3.5MG

DESCRIPTION

Bortezomib is sold under the brand name Velcade 3.5mg which is a type of anti-cancer medicine, which is in the form of lyophilized powder
A first beneficial proteasome inhibitor is known as Velcade 1mg; proteasome is a cellular structure which breaks the proteins.
Velcade 3.5mg injection will helps to prevent from multiple myeloma in patients with or without before treatment history and mantle cell lymphoma.

Velcade 3.5mg 

INDICATION

Multiple myeloma :
Velcade 3.5mg is indicated to treat the patients suffering from multiple myeloma.
Mantle cell lymphoma :
Velcade 3.5mg injection is indicated to treat the disease mantle cell lymphoma which the patients have received at least 1 prior therapy.

MECHANISM OF ACTION

Velcade 3.5mg injection used in mammalian cells is a reversible inhibitor of the chymotrypsin-like activity of the 26-S proteasome. The drug prohibits targeted proteolysis that affects multiple signaling cascades responsible for normal homeostatic functions within the cell, leading to cell death.

Velcade 3.5mg 

PHARMACOKINETIC

ABSORPTION
The peak plasma concentration after 1st dose is 57 and 112ng/mL, Ifadministrated two times a week, Cmax observed for 1mg/m2dose is 67 to 106ng/mL, for 1.3mg/m2 is 89 to 720ng/mL.
DISTRIBUTION
human serum plasma concentration is >80%
METABOLISM
Velcade 1mg injection metabolized mainly through cytochrome P450 isoenzymes CYP3A4, CYP2C19 & CYP1A2.
ELIMINATION
The excretion pathways of Velcade have not been characterized.
The terminal elimination of half-life after the 1mg/m2 dose is 40hrs - 193hrs, after dose 1.3mg/m2 is 76hrs - 108hrs.

DOSAGE AND ADMINISTRATION

Velcade is administrated alone or combination with dexamethasone
Three-week course is considered as therapy cycle
At least 72 hours must slip away between constant doses of Velcade
• Velcade (lyophilized powder form) is reconstituted by using 0.9% sodium chloride (NS)
• Velcade should be reconstituted in 3.5ml NS
• The route of administration is IV bolus
• Intrathecal not use for administration
In adults: 

Velcade 3.5mg 

MANTLE CELL LYMPHOMA

The Velcade recommended dose for untreated mantle cell lymphoma is;1.3mg/m2 of Velcade administered as IV bolus given as two times weekly by combining with rituximab, cyclophosphamide, doxorubicin and tablet prednisolone for two weeks (day I, IV, VIII & XI) followed rest period of 10 days (day II through 21).
In Relapse stage: The normal dose of Velcade is 1.3mg/m2 administered as IV bolus or subcutaneous two times for two weeks (day I, IV, VIII & XI) followed by 10-day rest period (day II through 21)
The therapy should follow for above 8 cycles may be given for once weekly for 4 weeks (day 1, 8, 15 & 22), followed by 13 day rest (days 23 through 35)

MULTIPLE MYELOMA

In the therapy of previously untreated multiple myeloma:1.3mg/m2 of dose must be given as 3 to 5 seconds through IV bolus or subcutaneous by concomitant use with tablet melphalan and prednisolone for nine 6 weeks therapy cycles
Cycles 1 over 4, Velcade is administrated for two times weekly, (day 1, 4, 8, 11, 22, 25, 29 and 32)
Cycles 5 over 9, Velcade is administrated once a week (day 1, 8, 22, and 29)

KEY POINTS
Moderately, 72 hours should be passing between following doses of Velcade 3.5mg 

IN RELAPSE STAGE
The usual dose of Velcade is 1.3mg/m2 should be administered through IV bolus or subcutaneous as two times for two weeks (day1, 4, 8, and 11) continued by a ten day of rest course (day 12 through 21) The schedule of the treatment has been raised above 8 cycles may be taken once weekly for 4 weeks (day 1, 8, 15, and 22), followed by 13 day rest (day 23 over 35)

PRECAUTIONS

While taking Velcade 3.5mg some adverse effects occurs care should be taken in the conditions like
Velcade 3.5mg injection leads to peripheral neuropathy like burning sensation, hyperesthesia, hypoesthesia, paresthesia, neuropathic pain
Manage postural Hypotension by altering the antihypertensive agents, hydration, and administration of mineralocorticoids or sympathomimetics
Cardiac toxicity :
Pulmonary toxicity like Acute Respiratory Distress Syndrome, pneumonitis, interstitial pneumonia, lung infiltration Posterior reversible encephalopathy syndrome-stop the Velcade 3.5mg therapy
Gastrointestinal toxicity-fluid or electrolyte replacements have to take :
Thrombocytopenia and neutropenia
Tumor lysis syndrome
Hepatic toxicity
Embryo fetal toxicity

Velcade 3.5mg 

SIDE EFFECTS

MOST COMMON SIDE EFFECTS

After administration of Velcade 3.5mg injection Most common side effects are occurred which includes; Black tarry stools ; Bleeding gums ; Blood in urine ; Blurred vision ; Body aches ; Burning, crawling, itching, numbness, prickling ;Chest pain ; Cough producing mucus, dizziness, faintness, nerve pain, painful urination, pale skin, runny nose, sore throat, stuffy nose, swollen glands, sunken eyes, ulcer, dry mouth, ear congestion, loss of voice

LESS COMMON SIDE EFFECTS

loss of appetite, Muscle cramps Belching, bone pain, difficulty with moving & bowel movements, cold and shivering, , loss of taste, , muscle pain, stomach discomfort. Vomiting, loss of weight; irregular breathing , Swelling of peripheral organs ,Dilated veins, discomfort, increased sensitivity of pain & touch, , heart beats, , thickening of bronchial secretions

PREGNANCY & LACTATION

Velcade 3.5mg is not recommended in pregnancy condition, it causes harm to fetus
Breast feeding is not recommended.

STORAGE

Velcade 3.5mg injection vial should be stored at 20°C to 25°C (68°F to 77°F) excursion between 15°C to 30°C (59°F to 86°F).
Keep away from light and heat.

CONTACT US

MAIL ID : millionhealthpharmaceuticals@gmail.com
PHONENO : +91-9940472902
WEBSITE : https://millionpharma.com/bortezomib-3.5mg.php